Choline

Clinical Summary

Choline is a conditionally essential nutrient required for cell membrane synthesis (phosphatidylcholine), neurotransmitter production (acetylcholine), lipid transport (VLDL assembly), and methyl group donation (one-carbon metabolism via betaine). Approximately 90% of Americans consume below the Adequate Intake, though the clinical significance of suboptimal intake in people eating varied diets remains debated.

The strongest evidence supports choline for preventing hepatic steatosis (NAFLD/TPN populations), fetal neurodevelopment during pregnancy, and cognitive function in mild cognitive impairment (alpha-GPC/CDP-choline forms specifically). The compound exists in multiple supplemental forms with dramatically different bioavailability and CNS penetration — form selection is as important as dose.

Key considerations: ~44% of the population carries PEMT gene variants impairing endogenous synthesis, increasing dietary requirements. Postmenopausal women and men have ~30% lower endogenous production than premenopausal women (estrogen-dependent PEMT pathway). Choline is metabolized by gut bacteria to trimethylamine (TMA) → TMAO, an emerging cardiovascular biomarker of uncertain clinical significance. A landmark 2024 discovery identified SLC25A48 as the mitochondrial choline transporter (PMID: 39111307), directly coupling choline to mitochondrial metabolism. A 2025 review established choline as a key immunomodulator required for macrophage and T-cell activation (PMID: 40821837).

Who benefits most: pregnant/lactating women, TPN-dependent patients, individuals with PEMT/MTHFR polymorphisms, elderly with cognitive decline, NAFLD patients, and vegans with low dietary choline.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7–9=strong causal | 5–6=moderate | 3–4=weak | 1–2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend:

Prescribing

Dosing Table

Formulation Table

Condition-Specific Protocols

NAFLD/MASLD Protocol

Evidence: 5/5 | Key PMIDs: 17490963, 39536658

Phase 1: Assessment (Week 0)

• Baseline: ALT, AST, GGT, lipid panel, hepatic ultrasound or FibroScan
• Plasma choline if available (target >10 µmol/L)
• Genotype PEMT rs12325817 if accessible

Phase 2: Therapeutic (Weeks 1–12)

• CDP-choline 500 mg BID or PC 1200–1800 mg/day with fat-containing meals
• Total choline 1000–2000 mg/day from diet + supplements
• Continue weight management, exercise, diabetes control as primary interventions

Phase 3: Maintenance (Week 12+)

• Recheck ALT/AST at 3 and 6 months; hepatic imaging at 6–12 months
• Expected: 10–30% ALT/AST reduction, improved steatosis on imaging
• Reduce to 550–700 mg/day maintenance if labs normalize

Stop/Reassess: No improvement at 12 weeks → investigate other causes. New GI symptoms → reduce dose.

Pregnancy Neurodevelopment Protocol

Evidence: 4/5 | Key PMIDs: 29217669, 40077755

Phase 1: Preconception through 1st Trimester

• Ensure dietary choline ≥450 mg/day + folate ≥800 mcg
• Add 400 mg choline bitartrate if diet insufficient (check prenatal vitamin — most have 0–55 mg)

Phase 2: 2nd–3rd Trimester (Critical Window)

• Target 550–930 mg/day total; 930 mg/day is the researched higher dose
• Choline bitartrate (cost-effective) or PC (dual benefit)
• Food sources to emphasize: eggs (147 mg/egg), beef liver (356 mg/3 oz)

Phase 3: Lactation

• Maintain 550–650 mg/day; breast milk choline reflects maternal stores
• No routine monitoring needed; safe up to 3,500 mg/day

Expected Outcomes: Improved infant processing speed (+33 ms at 13 mo), sustained attention at age 7, reduced NTD risk 25–30% (with folate).

Cognitive Decline (MCI) Protocol

Evidence: 4/5 | Key PMIDs: 36683513, 39300341

Phase 1: Initiation (Weeks 1–4)

• Alpha-GPC 400 mg BID (building to TID)
• Baseline MoCA or MMSE; plasma choline if available
• Rule out B12 deficiency, hypothyroidism, depression

Phase 2: Therapeutic (Weeks 4–24)

• Alpha-GPC 400 mg TID (1200 mg/day) OR CDP-choline 500 mg BID
• Head-to-head meta-analysis (2025) favors alpha-GPC over citicoline on global clinical ratings
• Monitor for cholinergic side effects (GI, sweating) if on cholinesterase inhibitors

Phase 3: Maintenance (Week 24+)

• Continue at therapeutic dose if benefit observed; reassess MoCA at 6 and 12 months
• Expected: 2–5 MMSE point improvement; slower cognitive decline trajectory

Drug Interaction Timing: If on donepezil/rivastigmine: start choline at 400 mg/day, titrate slowly. Monitor for excessive salivation, bradycardia, GI distress.

Safety

Interactions Table

Contraindications

• Absolute: Trimethylaminuria (TMAU/FMO3 deficiency) — worsens fishy odor profoundly
• Absolute: Known hypersensitivity to choline compound or excipients
• Relative: Active SIBO — gut bacteria ferment choline → TMA → worsening symptoms; defer until treated
• Relative: Established CVD + high TMAO production — avoid >1 g/day; prefer food sources

Adverse Effects (ranked by frequency)

FAERS Signal Table (from BioMCP)

FAERS interpretation: Total reports: ~1,766. Nearly ALL are for Choline C-11 Injection (PET radiotracer for prostate cancer), succinylcholine (neuromuscular blocker), or bethanechol (bladder drug). Choline bitartrate as suspect drug: 2 total reports (GERD, aspiration pneumonia — unrelated). No oral choline supplementation safety signal detected in FAERS. Per vault FAERS noise guidelines, these data are not clinically relevant to supplement safety assessment.

Citicoline suspect-only: Drug interaction (45), hypertension (44), off-label use (35). Alpha-GPC suspect-only: asthenia (15), pneumonia (15), diarrhoea (13). These come from clinical populations receiving these compounds as medications (not supplements) and reflect underlying disease burden.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Choline is hepatoprotective — deficiency causes steatosis. However, patients with established cirrhosis have impaired PEMT function and altered choline metabolism.

Synergies & Stacking

One-carbon metabolism optimization stack: Choline 550 mg + Folate 800 mcg (5-MTHF) + B12 1000 mcg (methylcobalamin) + B6 10–25 mg + Betaine 500–1000 mg. Especially beneficial for MTHFR C677T homozygotes.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Genetic polymorphisms define differential metabolite responses to choline forms — bitartrate vs PC produces different signatures depending on MTHFR/PEMT/BHMT genotype (PMID: 41415850). Precision nutrition based on genotype is emerging but not yet clinically actionable.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-positive across ~thousands of reports. Choline is regarded as "foundational infrastructure" rather than a standalone star. Extremely high individual variability — "your mileage may vary" is the most repeated phrase.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• Affiliate marketing saturation: Nootropics Depot, Mind Lab Pro, Performance Lab run active affiliate programs; many "independent" reviews are paid
• No identified MLM schemes specifically for choline products
• Huberman protocol dominance: Single-influencer monoculture risk — 300 mg alpha-GPC + garlic is widely adopted but never tested as a protocol
• "92% deficient" marketing claim: Conflates "below AI" with "clinically deficient" — overstates the case for most people eating eggs and meat
• No clear astroturfing detected for choline (unlike some peptide/proprietary markets)

Folk vs Clinical Reality Check

Community experience broadly aligns with clinical evidence for cognitive effects in deficient/elderly populations, liver benefits from PC, and GI side effects at high doses. The major divergences are: (1) community doses trend 30–50% lower than clinical trial doses, yet users still report effects — possibly because trials studied impaired populations while community members are starting from deficiency; (2) "choline depression" is well-documented in communities but barely studied clinically — the cholinergic hypothesis of depression provides mechanistic support; (3) the alpha-GPC vs CDP-choline debate is unresolved in both communities and literature — head-to-head data is sparse.

Deep Dive: Mechanisms & Research

Key Mechanisms (with clinical translation status)

1. Phosphatidylcholine synthesis (Kennedy pathway) — Choline → phosphocholine → CDP-choline → phosphatidylcholine. PC comprises 40–50% of membrane phospholipids. Deficiency rapidly impairs membrane integrity, especially in hepatocytes and neurons. Clinical translation: YES — NAFLD, TPN steatosis, membrane repair.

2. Acetylcholine production — Choline + acetyl-CoA → ACh via choline acetyltransferase. High-affinity choline uptake (HACU) is rate-limiting during high neuronal activity. Clinical translation: PARTIAL — cognitive decline responds; healthy enhancement does not.

3. Methyl group donation (one-carbon metabolism) — Choline → betaine (mitochondrial oxidation) → homocysteine remethylation to methionine → SAMe (universal methyl donor for >200 reactions). Clinical translation: YES — homocysteine lowering, epigenetic regulation, DNA methylation.

4. VLDL assembly and lipid export — PC is essential for VLDL particle assembly in hepatocytes. Without it, triglycerides accumulate → steatosis. Clinical translation: YES — the direct mechanism behind choline's hepatoprotective effect.

5. Mitochondrial metabolism (novel) — SLC25A48 identified as the mitochondrial choline transporter (PMID: 39111307, Cell Metab 2024). Directly couples choline to mitochondrial function. Clinical translation: NOT YET — too early; but links choline to energy metabolism.

6. Immune cell activation (novel) — Choline required for macrophage inflammatory activation via PC membrane remodeling; T-cell proliferation depends on choline-derived phospholipid membrane expansion (PMID: 40821837, Front Immunol 2025). Clinical translation: NOT YET — no supplementation trials for immune outcomes.

Emerging Research

• TMAO-targeting therapeutics: AstraZeneca discovered potent small-molecule inhibitors of gut bacterial choline-to-TMA conversion (PMID: 41614677, J Med Chem 2026). Could decouple choline supplementation from TMAO risk.
• Precision nutrition: MTHFR/PEMT/BHMT genotype determines metabolite responses to different choline forms (PMID: 41415850). Genotype-guided formulation selection is coming.
• Cardiac choline-ACh axis: Impaired cardiac non-neuronal ACh synthesis triggers mitochondrial dysfunction and heart failure (PMID: 41190780). Novel cardiovascular role.
• GWAS discoveries: Novel genetic loci influencing circulating choline/betaine/DMG identified (PMID: 40871658).

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Regulatory Status (from BioMCP)

• FDA: Not approved as drug. Recognized as essential nutrient. GRAS status for food use. UL 3,500 mg/day (IOM 1998). Citicoline: investigational drug in US; approved in Europe for stroke.
• EMA: No approved choline supplement product. Linzagolix choline (Yselty) authorized for uterine fibroids — choline is the salt form, not the active moiety.
• EFSA: AI of 400 mg/day for adults (2016). No UL set due to insufficient adverse effect data.
• Regulatory context: Choline is not commercially interesting as a pharmaceutical — it's an unpatentable essential nutrient. Most investment goes toward premium forms (alpha-GPC, citicoline) where markup justifies IP protection.

Ataraxia Verdict (as of 2026-04-15)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Cherry-picking: Nootropic marketing emphasizes alpha-GPC meta-analysis (PMID: 36683513) while ignoring that subjects were elderly with MCI — not healthy young adults seeking "cognitive enhancement"
• Hasty generalization: Alpha-GPC stroke risk (Lee 2021 Korean cohort) extrapolated from prescribed medication in cognitively declining elderly to healthy supplement users — confounding by indication almost certain
• Appeal to nature: "Get it from eggs, not pills" faction ignores that egg-derived choline has different TMAO kinetics, not different choline
• Argument from popularity: "Essential nutrient that 90% are deficient in" — conflates inadequate intake (below AI) with clinical deficiency (organ dysfunction). The AI was set by expert opinion, not rigorous dose-response RCTs
• Appeal to authority: Zeisel cited repeatedly as sole authority on choline requirements; his lab established the AI levels — circular evidentiary support

Evidence Gaps

• TMAO causality: Does choline supplementation (vs dietary choline) actually increase CVD events? No RCTs address this. Observational TMAO data cannot establish causation.
• Optimal pregnancy dose: 930 mg/day studied vs 480 mg/day, but dose-response curve unknown. Is 600 mg enough? Is 1200 mg better?
• Choline depression: Community reports of mood worsening at >500 mg/day are well-documented but barely studied clinically. The cholinergic hypothesis of depression (excess ACh → depressive state) provides a mechanism.
• Long-term high-dose safety: Most RCTs are 3–6 months. No multi-year safety data for >1 g/day.
• Healthy cognitive enhancement: Does choline improve cognition in healthy, non-deficient adults? Current evidence says probably not.
• Genotype-guided dosing: PEMT/MTHFR/BHMT variants alter requirements but no clinical protocols for genotype-stratified dosing exist.
• Immune function: New mechanistic evidence (PMID: 40821837) but zero supplementation trials for immune outcomes.

Bias Flags (Mode 4: First Principles)

• Industry funding: Most alpha-GPC and citicoline RCTs are industry-funded. Independent replication is limited. Meta-analyses inherit this bias.
• Zeisel monopoly: One research group (University of North Carolina) established most of the foundational choline evidence. Scientific consensus built on a narrow evidentiary base.
• AI vs RDA: Choline has an AI (Adequate Intake), not an RDA (Recommended Dietary Allowance) — meaning the evidence was insufficient to set a rigorous requirement. The "90% deficiency" narrative rests on this weaker standard.
• Form conflation: Studies using alpha-GPC or CDP-choline are cited to support "choline" supplementation generally, but bitartrate (the cheapest form) has minimal CNS evidence. Consumers buying budget choline may not get the studied effects.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Premium forms (alpha-GPC at $$$$, citicoline at $$$) heavily marketed for "brain health." Proprietary branded ingredients (Cognizin, AlphaSize) command markup with limited evidence of superiority over generic equivalents.
• Influencer economics: Huberman's alpha-GPC protocol drives significant supplement sales. While his coverage is more measured than most, the affiliate ecosystem around nootropic influencers (Nootropics Depot, Mind Lab Pro) is lucrative.
• Counter-narrative manipulation: TMAO fearmongering benefits: (a) researchers who built careers on the TMAO hypothesis; (b) competing supplement categories. Nobody profits from choline being safe AND effective — supplements sell on novelty and fear.
• Cui bono summary: Who wins if you take it: supplement manufacturers (especially premium forms); nootropic influencers with affiliate links. Who wins if you don't: competing supplement categories; TMAO researchers seeking relevance. Neither side is disinterested.
• Red team highlight: The most concerning angle is form conflation — consumers believe they're getting the studied effects from cheap bitartrate when the evidence actually applies to alpha-GPC/CDP-choline. This is not fraud but a systemic communication failure in the supplement industry.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 7/10 — essential nutrient with strong evidence for pregnancy/lactation, NAFLD, MCI, and PEMT/MTHFR carriers; broader utility depends on dietary adequacy (eggs/meat often sufficient) so general-population incremental benefit is modest.
• Opportunity cost: Choline bitartrate is cheap ($0.15–0.25/day); opportunity cost is low. Premium forms ($0.50–0.90/day) compete with better-evidenced supplements at the margin.
• Verdict: CONDITIONAL
• Conditions: (1) Pregnancy/lactation: ADD without question — 90%+ of prenatal vitamins are inadequate. (2) NAFLD/liver concern: ADD at therapeutic doses. (3) Cognitive decline/MCI (elderly): ADD alpha-GPC or CDP-choline. (4) PEMT/MTHFR carriers: ADD at higher maintenance. (5) Healthy adults eating eggs: SKIP supplementation unless other factors present. (6) Nootropic use in healthy young adults: WATCH — evidence insufficient.

Bottom Line

Choline is an authentic essential nutrient with rock-solid evidence for hepatic health and pregnancy neurodevelopment. For cognitive decline, alpha-GPC and CDP-choline show moderate benefit with industry-funding caveats. The "90% deficiency" narrative is overblown for people eating varied diets with eggs, but genuinely relevant for vegans, pregnant women, TPN patients, and PEMT carriers. TMAO concerns are real but unresolved — observational associations without causal proof. AstraZeneca's 2026 TMA-blocking compounds may eventually decouple this risk. The biggest consumer trap is form conflation: buying cheap bitartrate expecting premium-form effects. Choose form based on indication, not price alone.

Practical Notes

Brands & Product Selection

• CDP-choline: Cognizin (Jarrow, Life Extension, Doctor's Best) is the clinically studied branded form. Generic citicoline performs equivalently if third-party tested.
• Alpha-GPC: NOW Foods, Jarrow Formulas offer third-party tested options. AlphaSize is the branded equivalent.
• Bitartrate: NOW Foods, Bulk Supplements (transparent CoAs). Best value for non-CNS applications.
• Lecithin: Sunflower lecithin (NOW Foods) preferred over soy for allergen-free option.
• Quality markers: USP/NSF/ConsumerLab certification; cGMP facility; CoA available; exact elemental choline content on label. Red flags: proprietary blends, "pharmaceutical grade" without certification, no lot numbers.

Storage & Handling

• General: Room temperature (15–25°C), away from direct light, dry environment. Shelf life 2–3 years unopened, 12–18 months opened.
• Alpha-GPC powder: Highly hygroscopic — store with desiccant; clumps easily but potency unaffected.
• Lecithin (liquid): Must refrigerate after opening to prevent oxidation and rancidity.
• Degradation indicators: Discoloration, off-odor, persistent clumping (beyond normal hygroscopic behavior).

Palatability & Compliance

• Bitartrate/chloride: Bitter — mix with citrus juice, smoothies, or use capsules.
• CDP-choline/alpha-GPC: Mildly bitter — tolerable in water or coffee.
• Betaine (TMG): Slightly sweet, pleasant — easiest to mix.
• Lecithin granules: Nutty, mild — sprinkle on yogurt/oatmeal. Does not dissolve.
• Common dosing mistake: Confusing compound weight with elemental choline (1000 mg bitartrate = only 410 mg choline).

Exercise & Circadian Timing

• Pre-workout: Alpha-GPC 300–600 mg, 60–90 min before (limited evidence for power output; popular in community)
• Morning dosing preferred for all cognitive forms — ACh supports wakefulness/attention
• Avoid evening — high doses (>500 mg) can intensify dreams and disrupt sleep via REM enhancement
• Liver forms (bitartrate, lecithin) acceptable with dinner — aligns with overnight hepatic lipid metabolism

Reference Ranges (Expected Biomarker Changes)

Plasma choline is a poor long-term status marker — >95% of body choline is sequestered in phospholipids. Better functional markers: hepatic fat content (MRI), ALT/AST trends, homocysteine.

Cost

• Bitartrate: $0.15–0.25/day ($4.50–7.50/mo) — best value for maintenance/liver
• CDP-choline: $0.40–0.70/day ($12–21/mo) — best value for cognitive applications
• Alpha-GPC: $0.50–0.90/day ($15–27/mo) — premium for acute cognition/MCI
• Lecithin: $0.20–0.40/day ($6–12/mo) — good value for liver/low TMAO
• Betaine: $0.10–0.20/day ($3–6/mo) — cheapest for methylation support
• Bulk powder is 50–70% cheaper than capsules for long-term use.

What We Don't Know

• Whether choline supplementation (vs dietary choline) increases CVD events via TMAO — no RCTs exist
• The optimal pregnancy dose — 930 mg studied but dose-response curve unknown
• Whether healthy, non-deficient adults benefit cognitively from supplementation (probably not)
• Long-term (>2 year) safety of >1 g/day supplementation
• How to identify "high TMAO producers" clinically (gut microbiome testing not standardized)
• Whether garlic/allicin actually mitigates TMAO in vivo at supplement doses (never tested as combined protocol)
• The clinical significance of the SLC25A48 mitochondrial choline transporter discovery
• Whether choline affects immune function when supplemented (strong mechanism, zero trials)
• Genotype-guided dosing protocols for PEMT/MTHFR/BHMT carriers
• How "choline depression" works at the neurochemical level (cholinergic hypothesis plausible but unvalidated)
• True prevalence of functional choline deficiency (AI-based estimates are soft)
• Choline's role in hair, skin, bone, eye health, longevity — essentially unstudied
• Whether alpha-GPC actually increases stroke risk (confounded observational study; needs RCT clarification)
• If sex-specific dosing recommendations are warranted beyond the current AI adjustments

References

Systematic Reviews & Meta-Analyses

1. Sagaro GG et al. (2023) Alpha-GPC in adult-onset cognitive dysfunction: SR + MA. J Alzheimers Dis 92(1):59-70. PMID: 36683513 — SMD 0.56 (0.37–0.75), N=1,570 across 10 RCTs
2. Bonvicini M et al. (2023) Citicoline in dementia prevention: SR + MA. Nutrients 15(2):386. PMID: 36678257 — SMD 0.56–1.57; 6 studies
3. Sagaro GG, Amenta F. (2023) Choline phospholipids in stroke: SR + MA. J Clin Med 12(8):2875. PMID: 37109211 — Trend toward benefit; ICTUS negative
4. Heianza Y et al. (2017) TMAO and MACE: SR + MA. J Am Heart Assoc 6(7):e004947. PMID: 28663251 — HR 1.23 (1.07–1.42), N=19,256
5. Meyer KA, Shea JW. (2017) Dietary choline/betaine and CVD: SR + MA. Nutrients 9(7):711. PMID: 28686188 — RR 0.98 (0.93–1.03) — NOT associated
6. Gould JF et al. (2025) Choline + pregnancy + child neurodevelopment: SR. Nutrients. PMID: 40077755
7. Meta-analysis (2025) Choline for alcohol-exposed pregnancies. Pediatr Neonatol. PMID: 40251090

Landmark RCTs

8. Caudill MA et al. (2018) Maternal choline 930 vs 480 mg/day: infant processing speed. FASEB J 32(4):2172-2180. PMID: 29217669 — +33 ms at 13 mo
9. Fischer LM et al. (2007) Sex and menopausal status influence choline requirements. Am J Clin Nutr 85(5):1275-1285. PMID: 17490963 — 77% men/80% postmenopausal women: organ dysfunction on low-choline diet
10. Dávalos A et al. (2012) ICTUS trial: CDP-choline in acute stroke. Lancet 380:349-357. PMID: 22293558 — N=2,298; FAILED primary endpoint
11. Jeon JY et al. (2024) Alpha-GPC 600 mg/day in amnestic MCI: RCT. PMID: 39300341 — N=100; improved cognitive scores at 12 wk
12. Wurtman RJ et al. (2025) Cumulative 3-RCT report: choline in FASD preschoolers. Am J Clin Nutr. PMID: 39956364

Mechanism Studies

13. SLC25A48: mitochondrial choline importer. Cell Metab (2024). PMID: 39111307 — Major discovery
14. Choline in immunity: key regulator of immune cell activation. Front Immunol (2025). PMID: 40821837 — Landmark review
15. da Costa KA et al. (2006) PEMT polymorphisms and choline requirement. FASEB J 20(9):1336-1344. PMID: 16816108
16. Genetic polymorphisms define one-carbon metabolite responses to choline forms. Front Nutr (2025). PMID: 41415850
17. AstraZeneca TMA inhibitor discovery. J Med Chem (2026). PMID: 41614677
18. Choline metabolism in ischemic stroke: "two-edged sword." Pharmacol Res (2025). PMID: 40054542
19. Cardiac non-neuronal ACh synthesis and heart failure. Clin Sci (2025). PMID: 41190780
20. GWAS of circulating choline/betaine/DMG. Nutrients (2025). PMID: 40871658

Disease-Specific

21. Shaw GM et al. (2004) Periconceptional choline and NTDs. Am J Epidemiol 160(2):102-109. PMID: 15234930 — OR 2.42 for low intake
22. Zeisel SH et al. (1991) Choline essential nutrient: TPN steatosis. FASEB J 5(7):2093-2098. PMID: 2010061
23. Buchman AL et al. (1995) Choline deficiency and TPN hepatic steatosis. PMID: 7590654
24. Buchman AL et al. (2001) Choline supplementation in long-term TPN. PMID: 11531217
25. Buchman AL et al. (2001) Verbal/visual memory improvement with choline in TPN. PMID: 11190987
26. Salvadori E et al. (2021) Alpha-GPC + nimodipine in cerebral SVD. PMID: 33855653
27. Zhong C et al. (2021) Choline/betaine and post-stroke cognition. PMID: 33467878
28. Sohn BK et al. (2025) Alpha-GPC in T2D cognitive function. PMID: 39703111
29. Choline intake inversely associated with liver fibrosis/MASLD (NHANES). Maturitas (2025). PMID: 39536658
30. Citicoline neuroprotection in prodromal dementia: real-world data. Nutrients (2026). PMID: 41754112

Safety & Guidelines

31. Institute of Medicine (1998) DRIs for Choline. National Academies Press. — Established AI (550/425 mg/day) and UL (3,500 mg/day)
32. Bernhard W et al. (2024) Routine choline addition to TPN. PMID: 38931230
33. EFSA (2016) Adequate intake for choline. — AI 400 mg/day; no UL set

Observational & Other

34. Ueland PM. (2011) Choline and betaine in health and disease. J Inherit Metab Dis 34:3-15. PMID: 20446114
35. Oral choline improved neural efficiency in postmenopausal women. Nutrients (2026). PMID: 41683281
36. TMAO elevated in postmenopausal women. Exp Physiol (2026). PMID: 40684377
37. 3xTg-AD mice: lifelong low choline + sex-specific AD phenotypes. Aging Cell (2026). PMID: 41457719
38. Acute alpha-GPC enhances cognition in healthy men. Nutrients (2024). PMID: 39683633
39. Soy lysoPC vs GPC bioavailability (Japan RCT). Biosci Biotechnol Biochem (2024). PMID: 38490741
40. Low plasma lysoPC linked to reduced grip strength in elderly (Japan). Geriatr Gerontol Int (2026). PMID: 41360072